MBX Biosciences, Inc.

US$51.35As of Sun 8 Nov 2026, 12:00 UTC
NASDAQ:MBXHealthcare
Country USA
PE (Fwd) •••
TSR 2Y CAGR 38.21%
Div yield —
ROE (33.17%)
Biotechnology
Beta (5Y) 0.18
PE TTM —
TSR TTM 133.83%
Mkt cap US$2.473B
ROIC (23.29%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
$66
28.94%
(54.84%)
Hold 5|9|7|7|3
4Q25
1Q26
2Q26
3Q26
Earnings per share$
0.55
0.54
0.52
0.55
15.40%
9.39%
7.96%
10.63%
Revenue$M
174.5
169.8
179.8
186.1
0.87%
(0.19%)
6.42%
4.80%
Peers (US$2.473B)
Cap (US$)
PE
2.414B
—
Capital
TTM
5Y
10Y
Leveragex
0.414
(0.042)
(0.038)
EBIT/Intx
1.401
0.176
0.167
Own earn%
(357.75)
(30.00)
(55.09)
Sh yield%
37.07
79.88
76.61
Owners
Insiders/Inst%
11.13
24.42
Short interest%
2.11
SBC / revenue%
5.96
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
8
Op margin range%
22–27
$1 testx
0.8
Incr. ROIC%
20